tradmap

TRLV Trulieve Cannabis Corp.

$11.10 +8.19%

Data as of close

Healthcare · Medicinal Chemicals & Botanical Products

Trulieve Cannabis Corp. (TRLV) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $2.1 billion. Shares last traded at $11.10. Net profit margin is -41.8%, below the peer median of -8.8%. Revenue declined 0.4% year over year.

Market Cap
$2.1B
Shares Out
192.6M
EPS (TTM)
-$0.58
P/E (TTM)*
—
P/S Ratio
1.88
P/B Ratio
2.79
Dividend / Share
—
Dividend Yield
—
52-Week High
—
52-Week Low
—
Volume (venue)
111,926
Avg Vol (3m, venue)
68,959.333

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+2.59%
1M
+3.93%
3M
+25.42%
6M
—
YTD
-8.26%
1Y
—

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.35
SMA (50)
$11.20
SMA (200)
—
Price vs SMA50
-0.88%
Price vs SMA200
—
ATR (14)
$0.65

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$1.1B
Net Income
-$476M
Gross Margin
59.5%
Operating Margin
-24.3%
Net Margin
-41.8%
Return on Equity
-62.2%
Return on Assets
-22.9%
Current Ratio
5.94
Debt / Equity
0.26
Revenue Growth (YoY)
-0.4%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
FY 2025 -$0.58 2026-02-26
Q1 2025 -$0.16 2025-05-07
Q4 2024 (derived) -$0.27 2025-02-27
FY 2024 -$0.79 2025-02-27
Q3 2024 -$0.32 2024-11-05
Q2 2024 -$0.04 2024-08-06

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Medicinal Chemicals & Botanical Products peers

TRLV vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/S vs peers
1.88 / 0.58 med
+225% premium
Net margin vs peers
-41.8% / -8.8% med
below median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.4B———-10.70%
RGCRegencell Bioscience Holdings Ltd$3.1B———-5.00%
TRLVTrulieve Cannabis Corp.$2.1B—1.88-41.8%+8.19%
CRONCronos Group$1.2B17.646.8939.1%+1.52%
TLRYTilray Brands$375M—0.39-17.1%+0.40%
SNDLSNDL Inc.$337M———+2.81%
CGCCanopy Growth$288M—1.37-80.0%+4.07%
USNAUSANA HEALTH SCIENCES INC$271M—0.30-2.4%+2.69%
ACBAurora Cannabis$237M———+3.94%
GLASGlass House Brands Inc.$192M—1.05-16.3%+6.85%
NAGENiagen Bioscience, Inc.$190M11.881.4712.4%+2.56%
MDWDMediWound Ltd.$173M———+1.35%
FTLFFITLIFE BRANDS, INC.$78M12.450.776.2%+4.69%
BTMDbiote Corp.$33M5.560.183.2%+1.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.